Elucidating the specific pharmacological system of motion (MOA) of naturally transpiring compounds might be hard. Whilst Tarselli et al. (60) designed the primary de novo artificial pathway to conolidine and showcased that this naturally developing compound properly suppresses responses to both chemically induced and inflammation-derived discomfort